Reuters Health Information (2006-05-01): Human Genome says hepatitis C drug worked in combo
Drug & Device Development
Human Genome says hepatitis C drug worked in combo
Last Updated: 2006-05-01 9:13:52 -0400 (Reuters Health)
NEW YORK (Reuters) - Offering potential for the treatment of patients with hepatitis C, Albuferon(tm) may require less frequent dosing and fewer side effects than pegylated interferons,
Human Genome Sciences Inc. on Monday said interim results of a mid-stage trial of Albuferon, its experimental drug for hepatitis C, showed it succeeded at lowering the amount of the virus in the blood when taken in combination with another drug, ribavirin.
The company said the trial, which enrolled 115 patients, showed that the drug was also safe and well-tolerated.
The trial subjects, who had chronic hepatitis C, failed to respond to previous drug regimins, the company said.